WO2011152618A3 - 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 - Google Patents

국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 Download PDF

Info

Publication number
WO2011152618A3
WO2011152618A3 PCT/KR2011/003547 KR2011003547W WO2011152618A3 WO 2011152618 A3 WO2011152618 A3 WO 2011152618A3 KR 2011003547 W KR2011003547 W KR 2011003547W WO 2011152618 A3 WO2011152618 A3 WO 2011152618A3
Authority
WO
WIPO (PCT)
Prior art keywords
botulinum toxin
diffusive
causing local
muscle paralysis
local muscle
Prior art date
Application number
PCT/KR2011/003547
Other languages
English (en)
French (fr)
Other versions
WO2011152618A4 (ko
WO2011152618A2 (ko
WO2011152618A9 (ko
Inventor
정용훈
이현섭
Original Assignee
메덱스젠 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45067165&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2011152618(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2011262499A priority Critical patent/AU2011262499B2/en
Priority to JP2013513102A priority patent/JP5919608B2/ja
Priority to CN201180028634.2A priority patent/CN102985102B/zh
Priority to US13/700,867 priority patent/US9598683B2/en
Priority to ES11789976.5T priority patent/ES2659820T3/es
Application filed by 메덱스젠 주식회사 filed Critical 메덱스젠 주식회사
Priority to EP11789976.5A priority patent/EP2578228B1/en
Publication of WO2011152618A2 publication Critical patent/WO2011152618A2/ko
Publication of WO2011152618A9 publication Critical patent/WO2011152618A9/ko
Publication of WO2011152618A3 publication Critical patent/WO2011152618A3/ko
Publication of WO2011152618A4 publication Critical patent/WO2011152618A4/ko
Priority to US15/422,129 priority patent/US10369235B2/en
Priority to US15/422,083 priority patent/US20170145399A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

본 발명은 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소의 정제방법과 이에 의하여 정제된 비확산형 보툴리눔 독소에 관한 것으로서, 더욱 상세하게는 정제된 보툴리눔 독소 A 형 제제를 염화나트륨(NaCl)의 농도를 조절하여 첨가한 음이온 크로마토그래피를 수행하여 아분획을 분리하는 단계와 상기 아분획 중 A260/A280의 값이 일정범위인 분획을 수득하는 단계를 포함하여 이루어지는 비확산형 보툴리눔 독소의 정제방법과, 이에 의하여 정제된 것으로 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소에 관한 것이다.
PCT/KR2011/003547 2010-05-31 2011-05-13 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법 WO2011152618A2 (ko)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP11789976.5A EP2578228B1 (en) 2010-05-31 2011-05-13 Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof
JP2013513102A JP5919608B2 (ja) 2010-05-31 2011-05-13 局所筋麻痺効果を有する非拡散型ボツリヌス毒素とその精製方法
CN201180028634.2A CN102985102B (zh) 2010-05-31 2011-05-13 引起局部肌麻痹的非扩散型肉毒杆菌毒素及其精制方法
US13/700,867 US9598683B2 (en) 2010-05-31 2011-05-13 Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof
ES11789976.5T ES2659820T3 (es) 2010-05-31 2011-05-13 Toxina botulínica no difusiva que provoca una parálisis muscular localizada y procedimiento de purificación de la misma
AU2011262499A AU2011262499B2 (en) 2010-05-31 2011-05-13 Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof
US15/422,129 US10369235B2 (en) 2010-05-31 2017-02-01 Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof
US15/422,083 US20170145399A1 (en) 2010-05-31 2017-02-01 Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100051076A KR101134146B1 (ko) 2010-05-31 2010-05-31 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
KR10-2010-0051076 2010-05-31

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US13/700,867 A-371-Of-International US9598683B2 (en) 2010-05-31 2011-05-13 Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof
US15/422,083 Division US20170145399A1 (en) 2010-05-31 2017-02-01 Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof
US15/422,129 Division US10369235B2 (en) 2010-05-31 2017-02-01 Non-diffusive botulinum toxin causing local muscle paralysis, and purification method thereof

Publications (4)

Publication Number Publication Date
WO2011152618A2 WO2011152618A2 (ko) 2011-12-08
WO2011152618A9 WO2011152618A9 (ko) 2012-03-22
WO2011152618A3 true WO2011152618A3 (ko) 2012-05-24
WO2011152618A4 WO2011152618A4 (ko) 2012-07-12

Family

ID=45067165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/003547 WO2011152618A2 (ko) 2010-05-31 2011-05-13 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법

Country Status (8)

Country Link
US (3) US9598683B2 (ko)
EP (1) EP2578228B1 (ko)
JP (2) JP5919608B2 (ko)
KR (1) KR101134146B1 (ko)
CN (1) CN102985102B (ko)
AU (1) AU2011262499B2 (ko)
ES (1) ES2659820T3 (ko)
WO (1) WO2011152618A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101134146B1 (ko) * 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
KR101775682B1 (ko) * 2015-11-30 2017-09-06 주식회사 대웅 보툴리눔 독소의 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030060150A (ko) * 2002-01-07 2003-07-16 (주)메디톡스 클로스트리디움 보툴리눔 ａ형 독소를 정제하는 방법
KR20050074806A (ko) * 2004-01-14 2005-07-19 팜텍(주) 결정형 보툴리늄 독소의 제조방법
KR20090091501A (ko) * 2008-02-25 2009-08-28 메덱스젠 주식회사 클로스트리디움 보툴리눔으로부터 보툴리눔 독소를정제하는 방법

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE303567B (ko) * 1959-02-17 1968-09-02 Behringwerke Ag
US3409605A (en) * 1965-06-15 1968-11-05 American Cyanamid Co Concentration and purification of growth factor-placental origin (human)
AU2907695A (en) * 1994-08-08 1996-03-07 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US5939070A (en) * 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
AU2340299A (en) * 1998-01-26 1999-08-09 University Of Massachusetts Biologically active hemagglutinin from type a (clostridium botulinum) and methods of use
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
GB9921592D0 (en) * 1999-09-13 1999-11-17 Microbiological Res Authority Preparation of highly pure toxin fragments
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US6670322B2 (en) * 2000-06-01 2003-12-30 Wisconsin Alumni Research Foundation Method of targeting pharmaceuticals to motor neurons
KR100455280B1 (ko) 2000-06-28 2004-11-08 삼성코닝 주식회사 인듐 틴 옥사이드(ｉｔｏ)의 제조방법
DE10035156A1 (de) * 2000-07-19 2002-02-07 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel
JP2003009897A (ja) * 2001-07-03 2003-01-14 Keiji Oguma ボツリヌス毒素の分離・精製法
EP1491205A4 (en) * 2002-03-29 2007-04-25 Chemo Sero Therapeut Res Inst MEANS FOR THE TREATMENT OF HYPERMYOTONIA
US6673598B1 (en) * 2002-10-29 2004-01-06 Synthecon, Inc. Disposable culture bag
US7148041B2 (en) * 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
US7452697B2 (en) * 2003-09-25 2008-11-18 Allergan, Inc. Chromatographic method and system for purifying a botulinum toxin
US7160699B2 (en) * 2003-09-25 2007-01-09 Allergan, Inc. Media for clostridium bacterium and processes for obtaining a clostridial toxin
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US7064639B2 (en) * 2004-07-30 2006-06-20 Delta Systems, Inc. Electromagnetic latching switch
BRPI0508299A (pt) 2005-03-03 2007-07-31 Allergan Inc sistema livre de produto animal e processo para purificação de uma toxina botulina
US7465457B2 (en) * 2005-04-14 2008-12-16 Wisconsin Alumni Research Foundation Method for preparing botulinum neurotoxin type A light chain
KR101234969B1 (ko) 2005-06-03 2013-02-20 라이온 가부시키가이샤 지방산 저급 알킬에스테르의 제조 방법 및 지방산 저급알킬에스테르 및 경유 대체연료
US8949033B2 (en) * 2006-04-28 2015-02-03 The Chemo-Sero-Therapeutic Research Institute Method for quantification of neurotoxin
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
ES2537579T3 (es) * 2006-10-27 2015-06-09 The Chemo-Sero-Therapeutic Research Institute Preparación que contiene toxina botulínica de tipo A muy purificada derivada de patógeno de botulismo del lactante
CN101204577A (zh) * 2006-12-21 2008-06-25 中国人民解放军军事医学科学院微生物流行病研究所 一种a型肉毒毒素结晶复合物的制备方法
KR20090120222A (ko) * 2008-05-19 2009-11-24 (주)메디톡스 식물 유래 성분 함유 배지 및 가요성 폐쇄 용기를 이용하여클로스트리디움 보툴리눔 독소를 생산하는 방법
SG172812A1 (en) * 2008-12-31 2011-08-29 Revance Therapeutics Inc Injectable botulinum toxin formulations
US8440204B2 (en) * 2009-04-30 2013-05-14 Wisconsin Alumni Research Foundation Subtype of Closteridium botulinum neurotoxin type A and uses thereof
US8129139B2 (en) * 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
US20120196349A1 (en) * 2009-10-21 2012-08-02 Revance Therapeutics, Inc. Methods and Systems for Purifying Non-Complexed Botulinum Neurotoxin
EP2512519A2 (en) * 2009-12-18 2012-10-24 Allergan, Inc. Clostridium botulinum carrier complex for the administration of therapeutic agents
HUE029962T2 (hu) * 2010-01-25 2017-04-28 Allergan Inc Egyláncú fehérjék kétláncú formájúvá történõ intracelluláris konverziójának módszerei
KR101134146B1 (ko) * 2010-05-31 2012-04-19 메덱스젠 주식회사 국소 근마비 효과를 갖는 비확산형 보툴리눔 독소와 그의 정제방법
MX342920B (es) * 2010-07-30 2016-10-19 Medimmune Llc Metodo para purificar polipeptidos o inmunoconjugados activos.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030060150A (ko) * 2002-01-07 2003-07-16 (주)메디톡스 클로스트리디움 보툴리눔 ａ형 독소를 정제하는 방법
KR20050074806A (ko) * 2004-01-14 2005-07-19 팜텍(주) 결정형 보툴리늄 독소의 제조방법
KR20090091501A (ko) * 2008-02-25 2009-08-28 메덱스젠 주식회사 클로스트리디움 보툴리눔으로부터 보툴리눔 독소를정제하는 방법

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CARL, J. ET AL.: "Purification of Clostridium botulinum Type A Neurotoxin", METHODS IN MOLECULAR BIOLOGY: BACTERIAL TOXINS:METHODS AND PROTOCOLS, vol. 145, 2000, pages 27 - 39 *
GESSLER, F. ET AL.: "Production and purification of Clostridium botulinum type C and D neurotoxin", FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, vol. 24, 1999, pages 361 - 367, XP002343948 *

Also Published As

Publication number Publication date
CN102985102B (zh) 2016-06-08
WO2011152618A4 (ko) 2012-07-12
US10369235B2 (en) 2019-08-06
JP2013533856A (ja) 2013-08-29
JP5998419B2 (ja) 2016-09-28
AU2011262499B2 (en) 2015-01-22
WO2011152618A2 (ko) 2011-12-08
WO2011152618A9 (ko) 2012-03-22
EP2578228A2 (en) 2013-04-10
KR101134146B1 (ko) 2012-04-19
CN102985102A (zh) 2013-03-20
US20130071331A1 (en) 2013-03-21
AU2011262499A1 (en) 2013-01-24
EP2578228B1 (en) 2017-11-15
JP2015200659A (ja) 2015-11-12
EP2578228A4 (en) 2013-10-02
US20170145399A1 (en) 2017-05-25
JP5919608B2 (ja) 2016-05-18
ES2659820T3 (es) 2018-03-19
US9598683B2 (en) 2017-03-21
US20170143849A1 (en) 2017-05-25
KR20110131572A (ko) 2011-12-07

Similar Documents

Publication Publication Date Title
MX2019002904A (es) Composiciones de arn de alta pureza y métodos para su preparación.
BR112015004467A2 (pt) método para controlar a heterogeneidade de proteínas
WO2012170807A3 (en) Anti-pseudomonas psl binding molecules and uses thereof
MX340250B (es) Espumas emolientes para el tratamiento de dermatosis.
WO2013022997A3 (en) Small molecule compounds that control plant- and insect-pathogenic nematodes
WO2012051339A3 (en) Methods and compositions for treating respiratory conditions using platelet enriched plasma
SG10201811186XA (en) Purification of proteins
WO2010147650A3 (en) Treatment of particles for improved performance as proppants
MX364623B (es) Fragmentos mutantes de ospa y métodos y usos relacionados con estos.
WO2014043696A3 (en) Compositions and methods for treating amyotrophic lateral sclerosis
WO2013022740A3 (en) Gpr35 ligands and the uses thereof
MY167399A (en) Additive composition for control and inhibition of polymerization of styrene, and method of preparation and use thereof
WO2012017324A3 (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
BR112012025729A2 (pt) purificação por adsorção de caramelo
WO2011104315A3 (en) Immunoglobulin preparation and storage system for an immunoglobulin preparation
WO2013093096A8 (en) Ellagitannins rich extracts composition in sexual wellness
MX2017010763A (es) Nuevo anticuerpo que se una a tfpi y composicion que comprende el mismo.
UA105073C2 (uk) Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень
MX2014004633A (es) Una formulacion solida de paraquat y un metodo de preparacion de la misma.
BR112016001461A2 (pt) Método ou processo para modificar a fucosilação em um sistema de expressão de proteínas eucariótico e/ou eucariote, glicoproteína, e, uso de uma glicoproteína
MY166798A (en) Palm-based oil and method for producing same
WO2015017316A3 (en) Methods and compositions for modifying mucous membranes
WO2013022550A3 (en) Small molecule inhibitors of ebola and lassa fever viruses
AU2014370873A1 (en) Method for purifying antibody having low isoelectric point
MX359930B (es) Uso de ácido siálico, precursor de ácido siálico o una combinación de los anteriores para preparar medicamentos útiles en una condición diabética o síndrome nefrótico.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180028634.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11789976

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2013513102

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13700867

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2011789976

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011789976

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011262499

Country of ref document: AU

Date of ref document: 20110513

Kind code of ref document: A